Lung cancer: dropping bars or rising hoops--phase III outcomes of NSCLC.
Over the past three decades, the interpretation of clinical trial outcomes in studies of advanced-stage non-small-cell lung cancer has changed. The robustness of findings from these trials has been called into question. We believe this change is a reflection of the improved understanding of molecular-based therapeutics and continued advances in this field.
Department of Clinical Oncology, Faculty of Medicine, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin NT, Hong Kong SAR, China.
Herbert H
HH
Loong
Department of Clinical Oncology, Faculty of Medicine, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin NT, Hong Kong SAR, China.
Tony S K
TS
Mok
D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods* / Q000592:standards*; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000592:standards*; D016896:Treatment Outcome